Loading patent…
AssigneeEsperion Therapeutics, Inc.
InventorsCesare Sirtori, Guido Franceschini, Lars Abrahmsén, Erik Holmgren, Mats Lake, Björn Nilsson, Joanna Chmielewska, Peter Lind
Estimating the term…
Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.
A composition comprising isolated Apolipoprotein-AI-Milano dimer, wherein the dimer comprises two monomers and is purified to at least 90% homogeneity.
A method for the treatment of atherosclerosis or cardiovascular diseases comprising administering isolated Apolipoprotein AI Milano dimer comprising two monomers and purified to at least 90% homogeneity wherein the pharmaceutical composition further comprises a lipid lowering agent.
A method for the treatment of atherosclerosis and cardiovascular diseases, comprising administering isolated Apolipoprotein AI Milano dimer comprising two monomers and purified to at least 90% homogeneity, in a therapeutically active amount optionally with added carrier, stabilizing lipid compound and/or lipid lowering agent in a therapeutically active amount.
A process for preparing isolated Apolipoprotein AI Milano dimer comprising two monomers and purified to at least 90% homogeneity, comprising:
A process for preparing isolated Apolipoprotein AI Milano dimer comprising two monomers and purified to at least 90% homogeneity, comprising:
Dependencies are inferred from the claim text.